Pennsylvania Senate Committee Advances Cannabis Control Board Bill to Regulate Medical Marijuana and Hemp

A Pennsylvania Senate committee has moved forward with a bill to establish a Cannabis Control Board, aiming to overhaul oversight of the state's medical marijuana program and regulate hemp-derived products. The legislation, championed by Republican Sen. Dan Laughlin, seeks to address regulatory gaps in the fast-growing cannabis sector without immediately legalizing recreational marijuana. Laughlin emphasized, “This bill does not legalize adult-use cannabis, but eventually we probably will. If we have this board set up ahead of time, they can do it in a professional manner.”

Senate Bill 49 proposes transferring regulatory authority from the Department of Health to the new Cannabis Control Board, mirroring how gambling is managed in the state. Supporters argue this change would create a more agile regulatory framework, enabling faster responses to industry developments and ensuring consistent oversight. Laughlin stated, “The goal is obviously, if we create this board ahead of time, we can run all things cannabis in Pennsylvania in a professional manner.”

The bill has garnered backing from cannabis industry groups and some lawmakers previously hesitant about recreational legalization, while also facing criticism from proponents of broader reform. Monica McCafferty of Responsible PA, a cannabis business advocacy group, called the bill "a step forward," noting that “about 70 percent of Pennsylvanians do want adult-use legalization.” Licensed marijuana operators like Terrapin also support the bill, with Marcus Peter highlighting the need for safety standards: “By establishing a Cannabis Control Board, we can ensure that every operator—regardless of the product’s origin—meets the same high bar for consumer safety and lab-tested quality.”

A key focus of the legislation is the regulation of hemp-derived products such as delta-8 THC, which proliferated after the 2018 federal Farm Bill redefined hemp. These products currently evade stringent oversight and are often sold without age restrictions or quality controls, raising concerns from health officials and the FDA about potential risks to consumers. The bill aims to close this regulatory loophole, especially as federal definitions of hemp are set to tighten in November, which could further restrict THC content and ban synthetic cannabinoids in these products

Political dynamics in Pennsylvania remain complex. The Republican-controlled Senate is seen as the main barrier to full recreational legalization, despite growing support among Democrats and the public. Governor Josh Shapiro has repeatedly included cannabis legalization in his budget proposals, and House Democrats have passed related bills, only to see them stall in the Senate. Laughlin remains optimistic, citing shifting attitudes even among conservatives, especially following the federal move to reclassify cannabis and increased openness to reform

From the OG Lab newsroom perspective, the advancement of Senate Bill 49 marks a significant step toward modernizing Pennsylvania's cannabis oversight and could serve as a template for future recreational legalization. The bill’s emphasis on professional regulation and consumer safety reflects broader trends across the U.S. cannabis landscape. Stakeholders should closely monitor the board's establishment and the evolving federal hemp guidelines, as these developments could reshape market opportunities and regulatory expectations in Pennsylvania and beyond